Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET

Test-Retest Reproducibility of Binding Parameters in Humans with 11C-LY2795050, an Antagonist PET Radiotracer for the   Opioid Receptor

(2015) M. Naganawa et al.   JOURNAL OF NUCLEAR MEDICINE

Kinetic Modeling of 11C-LY2795050, A Novel Antagonist Radiotracer for PET Imaging of the Kappa Opioid Receptor in Humans

(2014) Mika Naganawa et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects

(2014) Stephen L. Lowe et al.   JOURNAL OF CLINICAL PHARMACOLOGY

An Improved Antagonist Radiotracer for the  -Opioid Receptor: Synthesis and Characterization of 11C-LY2459989

(2014) M.-Q. Zheng et al.   JOURNAL OF NUCLEAR MEDICINE

Evaluation of the agonist PET radioligand [11C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, test–retest reproducibility and receptor occupancy by the antagonist PF-04455242

(2014) Mika Naganawa et al.   NEUROIMAGE

The influence of different cellular environments on PET radioligand binding: An application to D2/3-dopamine receptor imaging

(2014) Darren R. Quelch et al.   NEUROPHARMACOLOGY

Development of κ Opioid Receptor Antagonists

(2013) F. Ivy Carroll et al.   JOURNAL OF MEDICINAL CHEMISTRY

Determination of In Vivo Bmax and Kd for 11C-GR103545, an Agonist PET Tracer for  -Opioid Receptors: A Study in Nonhuman Primates

(2013) G. Tomasi et al.   JOURNAL OF NUCLEAR MEDICINE

Determination of the In Vivo Selectivity of a New  -Opioid Receptor Antagonist PET Tracer 11C-LY2795050 in the Rhesus Monkey

(2013) S. J. Kim et al.   JOURNAL OF NUCLEAR MEDICINE

Synthesis and Evaluation of 11C-LY2795050 as a  -Opioid Receptor Antagonist Radiotracer for PET Imaging

(2013) M.-Q. Zheng et al.   JOURNAL OF NUCLEAR MEDICINE

Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects

(2012) Katherine A. MacLean et al.   PSYCHOPHARMACOLOGY

Repeated Exposure to the κ-Opioid Receptor Agonist Salvinorin A Modulates Extracellular Signal-Regulated Kinase and Reward Sensitivity

(2011) David N. Potter et al.   BIOLOGICAL PSYCHIATRY

Discovery of Aminobenzyloxyarylamides as κ Opioid Receptor Selective Antagonists: Application to Preclinical Development of a κ Opioid Receptor Antagonist Receptor Occupancy Tracer

(2011) Charles H. Mitch et al.   JOURNAL OF MEDICINAL CHEMISTRY

Neuropharmacology of the Naturally Occurring  -Opioid Hallucinogen Salvinorin A

(2011) C. W. Cunningham et al.   PHARMACOLOGICAL REVIEWS

Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum

(2010) Matthew W. Johnson et al.   DRUG AND ALCOHOL DEPENDENCE

Evaluation of the kappa-opioid receptor-selective tracer [11C]GR103545 in awake rhesus macaques

(2010) Bent W. Schoultz et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: A PET study in a receptor internalization-deficient mouse model

(2010) Mette Skinbjerg et al.   NEUROIMAGE

[11C]GR103545: novel one-pot radiosynthesis with high specific activity

(2010) Nabeel B. Nabulsi et al.   NUCLEAR MEDICINE AND BIOLOGY

Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen

(2009) Zeynep S. Teksin et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Salvinorin A and derivatives: Protection from metabolism does not prolong short-term, whole-brain residence

(2009) Jacob M. Hooker et al.   NEUROPHARMACOLOGY

30 years of dynorphins — New insights on their functions in neuropsychiatric diseases

(2009) Christoph Schwarzer   PHARMACOLOGY & THERAPEUTICS

Unconditioned Behavioral Effects of the Powerful  -Opioid Hallucinogen Salvinorin A in Nonhuman Primates: Fast Onset and Entry into Cerebrospinal Fluid

(2008) E. R. Butelman et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans

(2008) Jacob M. Hooker et al.   NEUROIMAGE